Skip to main content

Table 3 Anti-relapse efficacy of a total tafenoquine dose 1.8 mg/kg (0.6 mg/kg/day for three days or 1.8 mg/kg once) monotherapy or in combination with chloroquine and other blood stage regimens.

From: Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)

Treatment Cohort

Notes of clarification

Outcome

#cured/total (%)

TQ Alone*

  

Cohort 3

TQ given alone after quinine pretreatment

6/6 (100)

TQ + CQ 16

  

Cohort 1**

CQ given sequentially after blood stage failure of first tafenoquine treatment regimen

2/2 (100)

Cohort 2

CQ + TQ given simultaneously for first treatment

2/2 (100)

TQ + CQ 24

  

Cohort 1

CQ given sequentially after blood stage failure of first relapse treatment

2/2 (100)

Cohort 1

Treatment of second relapse

1/2 (50)

Cohort 2

CQ + TQ given simultaneously for first treatment

5/5 (100)

Cohort 3

TQ given with CQ after quinine pretreatment to eliminate blood stage parasites

6/6 (100)

Unpublished data

TQ given as a single dose for first treatment (data not shown)

2/2 (100)

TQ + Other Anti-malarials

  

Cohort 2

Simultaneous combination with artemether-lumefantrine for initial treatment

5/6 (83)

Unpublished data

Simultaneous combination with atovaquone-proguanil for initial treatment (data not shown)

2/2 (100)

Total

  

Tafenoquine alone

 

6/6 (100)

TQ + CQ

 

20/21 (95)

TQ + all BS**All

 

27/29 (93)

TQ

 

33/35 (94)

  1. * This refers to published data in which blood stage parasites were eliminated prior to tafenoquine or tafenoquine/chloroquine treatment. ** These are monkeys (Table 1) which were treated with chloroquine after tafenoquine monotherapy failed to clear blood stage parasites. For the purposes of the anti-relapse endpoint, these monkeys were considered to have been given a combination regimen. ** All blood schizonticidal drugs.